Antiplatelet drugs

Overview
Antiplatelet drugs prevent platelet aggregation and thrombus formation, primarily used in cardiovascular diseases like myocardial infarction and stroke. Aspirin (COX-1 inhibitor) irreversibly inhibits thromboxane A₂ (TXA₂) synthesis, reducing platelet activation. P2Y₁₂ receptor antagonists, such as clopidogrel, prasugrel, and ticagrelor, block ADP-mediated platelet activation and aggregation. GPIIb/IIIa inhibitors (e.g., abciximab, eptifibatide) prevent fibrinogen binding to platelets, disrupting clot formation. Phosphodiesterase inhibitors like dipyridamole increase cyclic AMP levels, inhibiting platelet activation and vasoconstriction.
4o
Learning outcomes
1. Definition and classification of Antiplatelet drugs
2. Difference between Anticoagulants, antiplatelets, & Fibrinolytics
3. Platelets & its receptor
4. Classification of Antiplatelet drugs
5. Aspirin
6. ADP receptor or P2Y12 receptor inhibitors
7. Phodiesterase inhibitors - Dipyridamole
8. GPIIb/IIIa inhibitors